澳华内镜(688212) - 2024 Q2 - 季度业绩预告

Financial Performance - Expected net profit attributable to parent company owners for the first half of 2024 is between 4.65 million yuan and 7 million yuan, a decrease of 31.08 million yuan to 33.43 million yuan year-on-year, representing a decline of 81.62% to 87.79%[3] - Expected revenue for the first half of 2024 is between 345.6 million yuan and 357.7 million yuan, an increase of 56.52 million yuan to 68.62 million yuan year-on-year, representing a growth of 19.55% to 23.74%[8] - Revenue for the first half of 2023 was 289.08 million yuan, with net profit attributable to parent company owners of 38.08 million yuan[4] - Excluding the impact of share-based payments, the expected net profit attributable to parent company owners for the first half of 2024 is between 45.8 million yuan and 48.15 million yuan, an increase of 1.26 million yuan to 3.61 million yuan year-on-year, representing a growth of 2.83% to 8.11%[8] - Excluding the impact of share-based payments, the net profit attributable to parent company owners for the first half of 2023 was 44.54 million yuan[10] Share-Based Payments and Equity Incentives - The impact of share-based payments on the first half of 2024 is approximately 41.15 million yuan[8] - The company conducted two rounds of equity incentives in 2022 and 2023, which significantly impacted the net profit for the reporting period[5] Revenue Growth Drivers - Revenue growth in the current period is attributed to increased product promotion, product upgrades based on clinical needs, and expanded coverage across hospitals of various levels[10] - The company's brand influence has been rising, positively impacting its operations[10] Forecast and Reporting - The forecasted data is preliminary and subject to change, with the final financial data to be disclosed in the official 2024 semi-annual report[12]